Edition:
United Kingdom

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

46.09USD
9:00pm BST
Change (% chg)

$-0.88 (-1.87%)
Prev Close
$46.97
Open
$46.12
Day's High
$46.96
Day's Low
$45.26
Volume
173,544
Avg. Vol
229,611
52-wk High
$82.68
52-wk Low
$33.06

Select another date:

Mon, Aug 27 2018

Esperion's combo therapy lowers cholesterol level by 35 percent, shares surge

Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study, sending the company's shares up as much as 11 percent.

UPDATE 1- Esperion's combo therapy lowers cholesterol level by 35 pct, shares surge

Aug 27 Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study, sending the company's shares up as much as 11 percent.

Esperion's cholesterol drug safe, effective in new late-stage study

May 23 Esperion Therapeutics said on Wednesday its cholesterol drug was safe and effective in treating heart disease patients in a new late-stage study, weeks after data from an earlier trial raised concerns about the treatment's efficacy.

BRIEF-Esperion Says Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint

* ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 LONG-TERM SAFETY STUDY OF BEMPEDOIC ACID

BRIEF-Esperion Posts Qtrly Loss Per Share $1.73

* ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

Select another date: